112 related articles for article (PubMed ID: 16619555)
1. Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy.
Nakamura R; Saikawa Y; Kubota T; Kumagai A; Kiyota T; Ohashi M; Yoshida M; Otani Y; Kumai K; Kitajima M
Anticancer Res; 2006; 26(2B):1433-7. PubMed ID: 16619555
[TBL] [Abstract][Full Text] [Related]
2. Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination.
Kubota T; Egawa T; Otani Y; Furukawa T; Saikawa Y; Yoshida M; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2003; 23(1B):583-7. PubMed ID: 12680150
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers.
Abe S; Kubota T; Matsuzaki SW; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M
Anticancer Res; 1999; 19(5C):4581-6. PubMed ID: 10650814
[TBL] [Abstract][Full Text] [Related]
4. Individualized adjuvant chemotherapy guided by chemosensitivity test sequential to extended surgery for advanced gastric cancer.
Iwahashi M; Nakamori M; Nakamura M; Noguchi K; Ueda K; Nakatani Y; Ojima T; Ishida K; Naka T; Yamaue H
Anticancer Res; 2005; 25(5):3453-9. PubMed ID: 16101163
[TBL] [Abstract][Full Text] [Related]
5. Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer.
Saikawa Y; Kubota T; Furukawa T; Suto A; Watanabe M; Kumai K; Ishibiki K; Kitajima M
Jpn J Cancer Res; 1994 Jul; 85(7):762-5. PubMed ID: 8071118
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of chemosensitivity test for advanced colorectal cancer.
Kabeshima Y; Kubota T; Watanabe M; Hasegawa H; Furukawa T; Kitajima M
Anticancer Res; 2002; 22(5):3033-7. PubMed ID: 12530038
[TBL] [Abstract][Full Text] [Related]
7. [Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination].
Nakamura R; Saikawa Y; Wada N; Yoshida M; Kubota T; Kumai K; Kitajima M; Kitagawa Y
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1827-31. PubMed ID: 18030017
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of chemosensitivity testing with highly purified tumor cells in 435 patients with gastric carcinoma using an MTT assay.
Noguchi K; Iwahashi M; Tani M; Nakamura M; Nakamori M; Nakatani Y; Ueda K; Ishida K; Naka T; Ojima T; Hotta T; Mizobata S; Yamaue H
Anticancer Res; 2005; 25(2A):931-7. PubMed ID: 15868930
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
10. [GRP78 expression in gastric cancer and its clinical significance].
Yang L; Yang SY; Ji JM; Cao YF; Ji CF; Ji JF; Xu WW; Wang JH
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):837-42. PubMed ID: 24447482
[TBL] [Abstract][Full Text] [Related]
11. [Impact of AJCC staging system (2010 edition) on the choice of postoperative adjuvant chemotherapy after radical resection of gastric cancer].
Yu YY; Liu TS; Wang ZM; Li W
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Jun; 15(6):599-602. PubMed ID: 22736131
[TBL] [Abstract][Full Text] [Related]
12. [Predictive chemotherapy of breast cancer directed by MTT assay in vitro].
Xu J; Song S; Tang Z
Zhonghua Zhong Liu Za Zhi; 1997 Mar; 19(2):153-6. PubMed ID: 10743085
[TBL] [Abstract][Full Text] [Related]
13. The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer.
Guo MG; Zheng Q; Cheng Z; Wang Y; Feng CN; Yang Z
Surg Oncol; 2010 Mar; 19(1):1-3. PubMed ID: 19006661
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
[TBL] [Abstract][Full Text] [Related]
15. FLEP chemotherapy for alpha-fetoprotein-producing gastric cancer.
Kochi M; Fujii M; Kaiga T; Takahashi T; Morishita Y; Kobayashi M; Kasakura Y; Takayama T
Oncology; 2004; 66(6):445-9. PubMed ID: 15452373
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
17. No cross-resistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assay.
Maeda S; Saikawa Y; Kubota T; Aoki M; Otani Y; Furukawa T; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2003; 23(4):3147-50. PubMed ID: 12926047
[TBL] [Abstract][Full Text] [Related]
18. Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma.
Zhibing W; Qinghua D; Shenglin M; Ke Z; Kan W; Xiadong L; Pengjun Z; Ruzhen Z
Hepatogastroenterology; 2013; 60(125):989-94. PubMed ID: 23598741
[TBL] [Abstract][Full Text] [Related]
19. [Recent advance in gastric cancer chemotherapy].
Kubota T
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2043-7. PubMed ID: 11103235
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
